Universal Flu Vaccine- The Future of Flu Treatment

NOIDA, India - Feb. 14, 2018 - PRLog -- Researchers, in different parts of the world, are developing universal vaccines for flu which will replace the annual flu shots. These universal vaccines will provide long-lasting protection against multiple strains of influenza virus. The universal vaccine will eliminate the need for updating and administrating the seasonal flu vaccine every year. It will also be able to provide protection against new stains which may cause flu pandemic.

As per RNCOS research report entitled, "Global Influenza Vaccine Market Outlook 2022", pharmaceutical companies and research institutes are making strategies to create a universal flu vaccine making use of the genetic component of the influenza virus that does not change over time.

Normally, a vaccine matched to a new influenza virus takes an approximate time of 6 months to get completed. On the contrary, a universal vaccine could be used immediately and could provide some protection against a newly emerging influenza virus that connoisseurs had not identified. A universal vaccine would abate the severity of disease, speed up the ability of the body to fight with the virus, and reduce the fatality rate of infections until a specific vaccine against that virus is available.

Furthermore, the mindset of people has changed in the past couple of years regarding awareness about flu and its treatment options. People have started getting vaccinated, rather than sticking to medicines for each type of flu and this has resulted in increased influenza vaccine demand. The healthcare services in developed countries are provided at such a high price that most of the people cannot afford them, so they prefer to take precautionary measures rather than paying hefty amount at the time of outbreak.

Numerous companies, such as Inovio and Vaccitech, are developing universal flu vaccines using different technologies to get rid of multiple vaccines. Vaccitech is currently planning a phase IIb in which 1500 -patient trial is scheduled to begin later in 2016.

For FREE SAMPLE of this report visit: http://rncos.viewpage.co/Global-Influenza-Vaccine-Market-Outlook-2022

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.